CSPC Pharmaceutical Group Limited · HKEX:1093
CSPC Pharmaceutical — Q1 2024 Earnings Presentation
36 slides from CSPC Pharmaceutical's earnings presentation, May 2024
Slide 1: 2024 1Q Results
1 ox sRoa SPC CSPC PHARMACEUTICAL GROUP LIMITED 2024 1Q Results - ' May 2024
Slide 2: China's Leading Innovative Pharmaceutical Enterprise
China’s Leading Innovative Pharmaceutical Enterprise R&D Capabilities Manufacturing Capabilities • 8 R&D platforms • 10+ pharmaceutical production bases • 5 R&D centres located in China & the U.S. • Nano formulation：27 production lines • ~ 2,000 R&D professionals built with production capacity of 20
Slide 3: 2024 1Q Highlights
2024 1Q Highlights R&D 1 new drug approvals: Results • Mingfule(AIS): first approved in China in similar products, which is the second indication • Revenue increased by 11.5% to RMB 8.98 B 18 IND approvals ： • Underlying profit attributable to China shareholders* (see page 6) increased 7 for the fir
Slide 4: Financial Highlights, Business Review, R&D Capabilities, Pipeline, BD & ESG
Financial Business R&D Pipeline BD & ESG Highlights Review Capabilities
Slide 5: Part 01 Financial Highlights
Part 01 Financial Highlights
Slide 6: Financial Highlights
Financial Highlights Unit: RMB’ M Revenue 2024 1Q 2023 1Q Change 8.98bn Revenue 8,983 8,053 +11.5% +11.5% 8.05bn Gross profit 6,495 5,519 +17.7% Gross profit margin 72.3% 68.5% +3.8% R&D expenses 1,169 1,008 +16.0% 2023 1Q 2024 1Q Underlying profit attributable to 1,724 1,545 +11.6% shareholders* Un
Slide 7: Revenue
Revenue Revenue by product category Finished drug revenue Unit: RMB’ M Unit: RMB ’M 2024 1Q 2023 1Q Change 2024 1Q 2023 1Q Change Finished drugs 7,561 6,422 +17.7% Nervous system 2,707 2,125 +27.4% Oncology 1,611 1,444 +11.6% 486 551 -11.8% Bulk vitamin C Anti-infective 1,350 Note: certain percentag
Slide 8: Operating Profit
Operating Profit Unit: RMB’ M 2024 1Q 2023 1Q 2024 1Q 2023 1Q Change Change OPM OPM Finished drugs 1,885 1,621 +16.3% 24.9% 25.2% -0.3% Bulk vitamin C 13 31 -60.1% 2.6% 5.7% -3.1% Bulk antibiotics 106 26 +301.7% 23.6% 5.7% +17.9% Functional Food 121 144 -15.7% 24.9% 23.4% +1.5% and Others Note: cert
Slide 9: Part 02 Business Review
Part 02 Business Review
Slide 10: Finished Drugs Overview by Therapeutic Areas
Finished Drugs Overview by Therapeutic Areas Nervous • Major products include NBP (butylphthalide soft capsules, butylphthalide and sodium chloride system injection), Shuanling (pentoxifylline extended-release tablets, pentoxifylline injection), Oulaining (oxiracetam capsules, oxiracetam for injecti
Slide 11: Key Products Overview: NBP, Mingfule, Ouyuexin
Key Products Overview NBP Mingfule Ouyuexin Butylphthalide soft capsules and injections Recombinant human TNK tissue-type Desvenlafaxine succinate extended- plasminogen activator for injection release tablets • 1st Class 1 new drug of cardio- • For thrombolytic therapy in patients with acute cerebro
Slide 12: Key Products Overview
Key Products Overview Jinyouli Duomeisu PEG-rhG-CSF Doxorubicin Hydrochloride liposome • 1st long-acting white blood cell booster drug injection in China • Largest market share in China • Expanding coverage in major municipal hospitals and county-level markets • The first player who passed • Was inc
Slide 13: Bulk Product Business, Functional Food and Others
Bulk Product Business, Functional Food and Others Bulk vitamin C Bulk antibiotics Functional food and others • Major products: vitamin C, • Major products: 7-ACA • Revenue of the functional food vitamin C - sodium, vitamin C - (intermediate), cefazolin and other business decreased， calcium and granu
Slide 14: Part 03 R&D Capability
Part 03 R&D Capability
Slide 15: R&D Overview
R&D Overview • 8 national science & • Approx.300 projects under • 87 national projects • 5 R&D centres located technology qualifications development (approx. 130 in China & the U.S. innovative drug projects) • RMB890M government • 2 state key labs grant support • R&D expenses in 2024 • 1856 IPs appl
Slide 16: Innovative R&D Platforms
Innovative R&D Platforms Nano- mRNA ADC formulation vaccine siRNA Mitoxantrone liposome Covid-19 mRNA PCSK9 siRNA and CLDN18.2 ADC Albumin-bound docetaxel vaccine 、RSV mRNA other chronic disease Paclitaxel cationic liposome vaccine and various Nectin-4 ADC drugs Cisplatin micelle pre
Slide 17: Nano-formulation Platform
Nano-formulation Platform Nano-formulation Novel Industrialized Novel drug carrier Novel drug delivery Novel preparation development and production technology design technology method manufacturing platform • Invented single-phase solution • Invented continuous flow • Invented Albumin • Invented amm
Slide 18: mRNA Vaccine Platform
mRNA Vaccine platform 1 Advantages of antigen 2 mRNA vaccine design 3 Manufacturing capabilities design • Mutation prediction platform • Base modification, UTR screening, • Manufacturing capabilities of CSPC codon optimization and structural • Top tier LNP R&D platform • The combination of bioinform
Slide 19: siRNA Platform
siRNA Platform 1 HTS screening platform 2 CMC platform 3 Manufacturing capabilities • Rational sequence design based • Build strong oligonucleotides • Manufacturing capabilities of on bioinformatics and CMC platform based on QbD CSPC experienced scientists strategy • Two GMP-compliant • Comprehensiv
Slide 20: ADC Platform
ADC Platform 1 Payload platform 2 Linker platform Multiple payload types for different cancer treatment mechanism of Various linker design for stability, PK and other purpose benefical for actions ADCs • microtubule inhibitor • Hydroflex platform ensures hydrophilicity, stability and PK • Topoisomer
Slide 21: Bispecific Antibody Platform
Bispecific Antibody Platform Antibody-interferon fusion protein platform Structural advantages • Synergistic binding effect when targeting the same cell High expandability : quickly forms new molecules • Smaller molecular weight (smaller than that of conventional antibodies) >20 times Safer impuri
Slide 22: Pipeline
Part 04 Pipeline 22
Slide 23: Candidates under Clinical Trial Stage
Candidates under Clinical Trial Stage （26） （15） (18) (7) PhI PhII (POC) PhII / III pivotal trial NDA NBL-012 NBL-015 NBL-020 CLDN18.2 CM326 JMT101 CM310 SYSA1802 IL23-P19 CLDN18.2 mAb TNFR2 ADC TSLP EGFR mAb IL4R PD-1 NBL-028 SYS6002 SYS6010 ALMB0166 ALMB0168 KN026 TG103 Omalizumab CLDN6-CD137 Necti
Slide 24: Pipeline - Biological Agents
Pipeline - Biological Agents Over 40 new biologic drugs under development: 2 filed BLA, 23 under clinical trial stage(9 under pivotal trial stage) and over 10 under pre-clinical stage Pre- Ph II / III TA Major Candidates Target Indication (s) Phase I Phase II NDA clinical pivotal trial JMT103 RANKL
Slide 25: Pipeline - Biological Agents
Pipeline - Biological Agents Ph II / III TA Major Candidates Target Indication (s) Pre-clinical Phase I Phase II NDA pivotal trial Nervous ALMB0166 CX43 antagonist Spinal cord injury, AIS system Digestion & TG103 GLP-1 Obesity, Diabetes metabolism Omalizumab biosimilar IgE Allergic asthma, CIU BLA U
Slide 26: Pipeline - Chemical Drugs
Pipeline - Chemical Drugs Over 40 small molecule new drugs under development: 1 filed NDA, 23 under clinical trial stage (4 under pivotal trial stage) and about 20 under pre-clinical stage Ph II / III TA Major Candidates Target Indication (s) Pre-clinical Phase I Phase II NDA pivotal trial DBPR108 D
Slide 27: Pipeline - New formulations
Pipeline - New formulations Over 30 new preparations under development: 2 flied NDA, 11 under clinical trial (5 under pivotal trial stage ), and over 20 under pre-clinical stage Phase III / TA Major Candidates Indication(s) Pre-clinical Phase I Phase II Pivotal Clinical NDA Trial Oncology Mitoxantro
Slide 28: Pipeline Products Launch Plan
Pipeline Products Launch Plan 13 Amoxetine 12 Anti-depressant Vaccine mRNA vaccine SYHX1901 Psoriasis 11 RSV Biological Agents Simertinib (TKI) mRNA vaccine SYHA1813 Solid tumors Chemical Drugs VZV 9 Brain glioma Paclitaxel cationic New formation liposome Cisplatin micelle TG103 Solid tumors UC/panc
Slide 29: Common Generics Launch Plan
Common Generics Launch Plan 17 applications have been filed for marketing approvals，expecting to receive approval in 2024-2025； Over 20 candidates under pharmaceutical research，expecting to receive approval in 2026-2027 No. Product Therapeutic Area Expected to be launched Launched or not Digestion &
Slide 30: IND Approvals Obtained since the beginning of 2024
IND Approvals Obtained since the beginning of 2024 IND approval for the 1st indication (7+2) JMT202 (mAb) Lower triglyceride (TG) levels in patients with hypertriglyceridaemia SYS6023 (ADC） Advanced solid tumors SYH2039 tablets（MAT2A） Advanced malignant tumors Dexmedetomidine hydrochloride nasal spr
Slide 31: IND Approvals Obtained since the beginning of 2024
IND Approvals Obtained since the beginning of 2024 IND approval for additional indications (9) In combination with CAPOX and SG001 or with irinotecan SYSA1801 injection hydrochloride liposome injection for first-line and second-line treatment of Claudin18.2-positive gastric cancer In combination wit
Slide 32: Part BD&ESG
Part 05 BD&ESG
Slide 33: BD Strategic Layout and Path of Advancement
BD Strategic Layout and Path of Advancement Focusing on strategic domains, deepening BD strategies, and establishing an international BD ecosystem BD Product Positioning：Aligning closely with clinical needs, emphasizing clinical benefits, grasping international cutting-edge technology and product tr
Slide 34: BD Key Therapeutic Area Strategy for 2024
BD Key Therapeutic Area Strategy for 2024 Reinforce Leading Position in Explore Novel Therapeutic Areas and Established Areas Technology Platforms • Comprehensive Management of Stroke • Address primary and • Concentrate on well- • Focus on therapeutic nuclear • Strengthen differentiation in hematolo
Slide 35: Aim to Become an ESG Leader in Pharmaceutical Industry
Aim to Become an ESG Leader in Pharmaceutical Industry • Awarded “China’s Top Healthiest Workplace” by Mercer, “AAA Enterprise with Harmonious Labour • Adhere to the procurement Continuous MSCI ESG Relations in Hebei Province” and principle of “fair, impartial, green and transparent” rating upgrade
Slide 36: Thanks!
WeChat of CSPC IR Team： Thanks！
CSPC Pharmaceutical Group — Q1 2024 Earnings Presentation on 6ix